196 related articles for article (PubMed ID: 31512706)
41. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
42. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
43. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
44. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
45. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
[TBL] [Abstract][Full Text] [Related]
46. Hyaluronic acid-modified yeast β-glucan particles delivering doxorubicin for treatment of breast cancer.
He F; Xie C; Xu X
Carbohydr Polym; 2023 Aug; 314():120907. PubMed ID: 37173014
[TBL] [Abstract][Full Text] [Related]
47. Self-targeted hyaluronic acid-b-poly (β-amino ester) pH-switchable polymersome for guided doxorubicin delivery to metastatic breast cancer.
Borhaninia M; Zahiri M; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Int J Biol Macromol; 2023 Sep; 248():125882. PubMed ID: 37473882
[TBL] [Abstract][Full Text] [Related]
48. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
49. Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles.
Pilapong C; Keereeta Y; Munkhetkorn S; Thongtem S; Thongtem T
Colloids Surf B Biointerfaces; 2014 Jan; 113():249-53. PubMed ID: 24103503
[TBL] [Abstract][Full Text] [Related]
50. Hyaluronan magnetic nanoparticle for mitoxantrone delivery toward CD44-positive cancer cells.
Sargazi A; Shiri F; Keikha S; Majd MH
Colloids Surf B Biointerfaces; 2018 Nov; 171():150-158. PubMed ID: 30025377
[TBL] [Abstract][Full Text] [Related]
51. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
[TBL] [Abstract][Full Text] [Related]
52. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
53. Surface Engineered Protein Nanoparticles With Hyaluronic Acid Based Multilayers For Targeted Delivery Of Anticancer Agents.
Pulakkat S; Balaji SA; Rangarajan A; Raichur AM
ACS Appl Mater Interfaces; 2016 Sep; 8(36):23437-49. PubMed ID: 27560126
[TBL] [Abstract][Full Text] [Related]
54. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells.
Hu K; Zhou H; Liu Y; Liu Z; Liu J; Tang J; Li J; Zhang J; Sheng W; Zhao Y; Wu Y; Chen C
Nanoscale; 2015 May; 7(18):8607-18. PubMed ID: 25898852
[TBL] [Abstract][Full Text] [Related]
55. Doxorubicin Hydrochloride-Loaded Mesoporous Silica Nanoparticles Inhibit Non-Small Cell Lung Cancer Metastasis by Suppressing VEGF-Mediated Angiogenesis.
Zhang M; Jiang L
J Biomed Nanotechnol; 2016 Nov; 12(11):1975-86. PubMed ID: 29363936
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and in vitro and in vivo evaluations of poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) magnetic nanoparticles containing doxorubicin as a potential targeted drug delivery system.
Hałupka-Bryl M; Asai K; Thangavel S; Bednarowicz M; Krzyminiewski R; Nagasaki Y
Colloids Surf B Biointerfaces; 2014 Jun; 118():140-7. PubMed ID: 24769390
[TBL] [Abstract][Full Text] [Related]
57. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice.
Kefayat A; Vaezifar S
Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043
[TBL] [Abstract][Full Text] [Related]
58. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
de Oliveira Silva J; Fernandes RS; Ramos Oda CM; Ferreira TH; Machado Botelho AF; Martins Melo M; de Miranda MC; Assis Gomes D; Dantas Cassali G; Townsend DM; Rubello D; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2019 Oct; 118():109323. PubMed ID: 31400669
[TBL] [Abstract][Full Text] [Related]
59. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
60. Hyaluronan decoration of milk exosomes directs tumor-specific delivery of doxorubicin.
Li D; Yao S; Zhou Z; Shi J; Huang Z; Wu Z
Carbohydr Res; 2020 Jul; 493():108032. PubMed ID: 32417443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]